UBS Downgrades Pharmasset (VRUS) to Neutral
More News related to VRUS
- Pharmasset Reports Fiscal Year End 2009 Financial Results
- Pharmasset (VRUS) Reports Inline Q4 Loss of $0.53
- Pharmasset (VRUS) and Roche Announce Continuing Enrollment for Cohort 2 Phase 2b
- Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
- Unusual 11 Mid-Day Movers 11/18: ABK, LZB, NLST, LDK Higher; ONCY, NANO, EXEL, VRUS Lower
More News related to Downgrades
- Piper Jaffray Initiates Coverage on Hain Celestial Group (HAIN) with a Neutral; Upside Potential is Limited
- Piper Jaffray Initiates Coverage on Green Mountain Coffee (GMCR) with an Overweight; Several Potential Catalysts
- Piper Jaffray Initiates Coverage on B&G Foods (BGS) with a Neutral; Stock Reflects Fair Valuation
- Piper Jaffray Initiates Coverage on Del Monte Foods (DLM) with a Neutral
- Longbow Starts KR, WFMI at Buy, SWY, SVU at Neutral
UBS downgrades Pharmasset (Nasdaq: VRUS) from Buy to Neutral.
Traders are shrugging off the UBS downgrade today, and buying shares of Pharmasset. The stock most recently traded at $10.49, up 3%.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
